Abstract
Bladder cancer has a very high frequency of recurrence and therefore requires close clinical surveillance throughout its life, with cystoscopies and serial cytological examinations. These tests are both invasive and expensive, with considerable interpersonal and inter-institutional variability. Moreover, cytological examination used for the diagnosis of low-grade tumors has a low sensitivity; thus, there is an increasing focus on the research for new, accurate, urinary markers. Herein, the biological basis, methodologies, and diagnostic performance of biomarkers are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
American Urological Association. (2016). Standard guideline statement emphasizing the role of urine cytology as biomarker. https://www.auanet.org/guidelines/bladder-cancer-nonmuscle-invasive
Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61:109–118, discussion 118
Riesz P, Lotz G, Páska C et al (2007) Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 13:187–194
Sassa N, Iwata H, Kato M et al (2019) Diagnostic utility of urovysion combined with conventional urinary cytology for urothelial carcinoma of the upper urinary tract. Am J Clin Pathol 151(5):469–478
Nagai T, Okamura T, Yanase T et al (2019) Examination of diagnostic accuracy of UroVysion fluorescence in situ hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients. Asian Pac J Cancer Prev 20(4):1271–1127
Kocsmár I, Pajor G, Gyöngyösi B et al (2020) Development and initial testing of a modified UroVysion-based fluorescence in situ hybridization score for prediction of progression in bladder cancer. Am J Clin Pathol 153(2):274–284
Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol Semin Orig Investig 26:646–651
He H, Han C, Hao L et al (2016) ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: a meta-analysis. Oncol Lett 12:83–88
Seideman C, Canter D, Kim P et al (2015) Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol 33:1309–1313
Kim PH, Sukhu R, Cordon BH et al (2014) Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in bladder cancer patients with negative surveillance cystoscopy. BJU Int 114:354–359
Savic S, Zlobec I, Thalmann GN et al (2009) The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 124:2899–2904
Miyake M, Goodison S, Giacoia EG et al (2012) Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol 12:23
Jamshidian H, Kor K, Djalali M (2008) Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J 5:243–247
Mowatt G, Zhu S, Kilonzo M et al (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess Winch Engl 14:1–331
Behrens T, Stenzl A, Brüning T (2014) Factors influencing false-positive results for nuclear matrix protein 22. Eur Urol 66:970–972
Hatzichristodoulou G, Kübler H, Schwaibold H et al (2012) Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA. Anticancer Res 32(11):5093–5097
Kumar A, Kumar R, Gupta NP (2006) Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 36(3):172–175
Grossman HB, Soloway M, Messing E et al (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299–305
Malkowicz SB (2000) The application of human complement factor h-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 27:63–73
Ellis WS, Blumenstein BA, Lm I et al (1997) Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 50(6):882–887
Cha EK, Tirsar L-A, Schwentner C et al (2012) Immunocytology is strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 61:185–192
Mian C, Maier K, Comploj E et al (2006) uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma. Cancer 108(1):60–65
Kavalieris L, O’Sullivan P, Frampton C et al (2017) Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol 197:1419–1426
Van Kessel KEM, Van Neste L, Lurkin I et al (2016) Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol 195:601–607
Van Kessel KEM, Beukers W, Lurkin I et al (2017) Validation of a DNA methylation mutation urine assay to select patients with hematuria for cystoscopy. J Urol 197:590–595
D Elia C, Pycha A, Folchini DM et al (2019) Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. J Clin Pathol 72:140–144
Pichler R, Fritz J, Tulchiner G et al (2018) Increased accuracy of a novel mRNA based urine test for bladder cancer surveillance. BJU Int 121:29–37
Hakenberg OW, Fuessel S, Richter K et al (2004) Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64:1121–1126
Ritter R, Hennenlotter J, Kühs U et al (2014) Evaluation of a new quantitative point of-care test platform for urine-based detection of bladder cancer. Urol Oncol 32:337–344
Lamarca A, Barriuso J (2012) Urine telomerase for diagnosis and surveillance of bladder cancer. Adv Urol 2012:693631
Kim NW, Piatyszek MA, Prowse KR et al (2011) Specific association of human telomerase activity with immortal cells and cancer. Science 1994:266
Mucciardi G, Gali' A, Barresi V et al (2014) Telomere instability in papillary bladder urothelial carcinomas: Comparison with grading and risk of recurrence. Indian J Urol 30:245
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Costantini, M., Gallo, G., Attolini, G. (2021). Urinary Biomarkers In Bladder Cancer. In: Salvi, S., Casadio, V. (eds) Urinary Biomarkers. Methods in Molecular Biology, vol 2292. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1354-2_11
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1354-2_11
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1353-5
Online ISBN: 978-1-0716-1354-2
eBook Packages: Springer Protocols